Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geriatric Syndromes Clear all
Terminated Phase 2 Interventional Results available

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

NCT01442714
View directory record Official record
Conditions
Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Interventions
Azacitidine, Lenalidomide
Drug
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 3, 2026, 11:37 AM EDT
Not listed No phase listed Observational

Cognition and the Immunology of Postoperative Outcomes

NCT04792983
View directory record Official record
Conditions
Cognitive Impairment, Frail Elderly Syndrome, Delirium, Surgery
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 3, 2026, 11:37 AM EDT
Recruiting Not applicable Interventional

Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

NCT02703207
View directory record Official record
Conditions
Obstructive Sleep Apnea, OSA COPD Overlap Syndrome
Interventions
Positive airway pressure, NIPPV and /or oxygen
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 3, 2026, 11:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

NCT02038153
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Interventions
Laboratory Biomarker Analysis, Lenalidomide
Other · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
The Bronx, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)

NCT01048242
View directory record Official record
Conditions
Insomnia, Obstructive Sleep Apnea
Interventions
rozerem, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 3, 2026, 11:37 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685
View directory record Official record
Conditions
Alport Syndrome
Interventions
BAY 3401016, Placebo
Biological · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Aged Garlic Extract on Atherosclerosis

NCT01534910
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
aged garlic extract, placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
40 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 3, 2026, 11:37 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

NCT07723963
View directory record Official record
Conditions
Juvenile Myoclonic Epilepsy
Interventions
JZP926 capsule, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Grapefruit or Grapefruit Juice on Anthropometry, Dietary Intakes, Appetite, and Metabolic Profile in Overweight and Obese Young and Middle-Aged Adults

NCT00581074
View directory record Official record
Conditions
Obesity
Interventions
diet (grapefruit or grapefruit juice)
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Not applicable Interventional Results available

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

NCT02121418
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Bozeman, Montana • Kennewick, Washington • Kirkland, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 3, 2026, 11:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Preoperative Cognitive Screening in Older Spinal Surgical Patients

NCT02922634
View directory record Official record
Conditions
Cognitive Impairment, Frail Elderly Syndrome
Interventions
Mini Cog
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
70 Years and older
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

NCT05197075
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
DRV/COBI FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 3, 2026, 11:37 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Aging, Geriatric Syndromes and Clonal Hematopoiesis

NCT02604563
View directory record Official record
Conditions
Geriatrics, Aged, Geriatric Syndromes, Cardiovascular Diseases
Interventions
Cognitive Assessment, Activities of Daily Living Questionnaire, Instrumental Activities of Daily Living, subscale of the OARS, Karnofsky Self-reported Performance Rating Scale, Number of Falls, Physical Health Section, subscale of the OARS, MOS Social Activity Survey, Unintentional Weight Loss, Peripheral Blood Draw, Buccal Swab, Heart Health and Smoking History from BRFSS questionnaire, Gait Speed, Grip Strength, Height and Weight measurements, Blood pressure measurement, Optional bone marrow biopsy, Blood draw for trauma measurements, Femur head donation, Knee bone fragments, Bone marrow aspirate
Other · Genetic · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Universal Anti-Viral Vaccine for Healthy Elderly Adults

NCT04441047
View directory record Official record
Conditions
Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia, Influenza, Human, ARDS, Human
Interventions
AlloStim
Drug
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Delray Beach, Florida • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

NCT01379183
View directory record Official record
Conditions
Healthy
Interventions
Erythromycin, Placebo, Magnetic Resonance Imaging, Barium Sulfate Solution
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 3, 2026, 11:37 AM EDT
Recruiting Not applicable Interventional

A Telehealth Advance Care Planning Intervention

NCT05875805
View directory record Official record
Conditions
Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
Interventions
Telehealth Serious Illness Care Program, Education Control
Behavioral · Other
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

NCT00799864
View directory record Official record
Conditions
HIV-1
Interventions
Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
6 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Syracuse, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

NCT00915655
View directory record Official record
Conditions
HIV-1 Infection
Interventions
darunavir, ritonavir, zidovudine, lamivudine, abacavir
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
12 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Not applicable Interventional Results available

P20 Extending Sleep to Reverse Metabolic Syndrome

NCT03596983
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Sleep Intervention, Week 2 Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
35 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Not applicable Interventional Results available

A Community Wellness Program for Adults Living With Long-term Physical Disability

NCT03653390
View directory record Official record
Conditions
Physical Disability
Interventions
EnhanceWellness for Disability (EW-D), Wellness Education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 64 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 3, 2026, 11:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Selumetinib granule formulation, Selumetinib capsule formulation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 3, 2026, 11:37 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

NCT07480564
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
2 Years to 3 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 11:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

NCT01969851
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Orlando, Florida • Henderson, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 3, 2026, 11:37 AM EDT